Crealta Pharmaceuticals LLC
Crealta Pharmaceuticals LLC, headquartered in the United States, is a prominent player in the biopharmaceutical industry, specialising in innovative therapies for rare diseases. Founded in 2013, the company has made significant strides in developing treatments that address unmet medical needs, particularly in the areas of pain management and rare conditions. Crealta's flagship product, Krystexxa, is a unique enzyme therapy designed for chronic gout patients who are refractory to conventional treatments. This product has positioned Crealta as a leader in the gout treatment market, showcasing the company's commitment to improving patient outcomes through advanced biopharmaceutical solutions. With a focus on research and development, Crealta continues to expand its portfolio, solidifying its reputation as a trusted name in the healthcare sector.
DitchCarbon Score
How does Crealta Pharmaceuticals LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Crealta Pharmaceuticals LLC's score of 52 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Crealta Pharmaceuticals LLC, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Amgen Inc., and any climate commitments or emissions data may be inherited from its parent organisation. As part of its corporate family, Crealta Pharmaceuticals may align with the sustainability initiatives and targets set by Amgen Inc., which operates under the Science Based Targets initiative (SBTi). However, specific reduction targets or achievements for Crealta Pharmaceuticals are not detailed in the available information. Additionally, emissions data may also be influenced by practices from Horizon Therapeutics Public Limited Company, from which Crealta Pharmaceuticals may inherit certain climate-related strategies. In summary, while Crealta Pharmaceuticals LLC has not disclosed specific emissions data or reduction targets, it is positioned within a corporate structure that prioritises climate commitments through its parent and related organisations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 144,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 290,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Crealta Pharmaceuticals LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
